New Journal Website is available at: http://www.journalonweb.com/rcm

Published by: Kowsar

Changes of High Sensitivity C-Reactive Protein During Clopidogrel Therapy in Patients Undergoing Percutaneous Coronary Intervention

Shokoufeh Hajsadeghi 1 , Mandana Chitsazan 2 , Mitra Chitsazan 3 , * , Negar Salehi 3 , 4 , Ahmad Amin 3 , Majid Maleki 3 , Nima Babaali 3 , Seifollah Abdi 3 and Maryam Mohsenian 1
Authors Information
1 Department of Cardiology, Rasoul-e-Akram Hospital, Iran University of Medical Sciences, Tehran, IR Iran
2 Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
3 Rajaei Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran
4 Michigan State University, Sparrow Health System, East Lansing, Michigan, USA
Article information
  • Research in Cardiovascular Medicine: February 2016, 5 (1); e28997
  • Published Online: December 16, 2015
  • Article Type: Research Article
  • Received: April 11, 2015
  • Revised: June 17, 2015
  • Accepted: July 19, 2015
  • DOI: 10.5812/cardiovascmed.28997

To Cite: Hajsadeghi S, Chitsazan M, Chitsazan M, Salehi N, Amin A, et al. Changes of High Sensitivity C-Reactive Protein During Clopidogrel Therapy in Patients Undergoing Percutaneous Coronary Intervention, Res Cardiovasc Med. 2016 ;5(1):e28997. doi: 10.5812/cardiovascmed.28997.

Abstract
Copyright: Copyright © 2016, Research in Cardiovascular Medicine. .
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999; 340(2): 115-26[DOI][PubMed]
  • 2. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105(9): 1135-43[PubMed]
  • 3. Torres JL, Ridker PM. Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events. Curr Opin Cardiol. 2003; 18(6): 471-8[PubMed]
  • 4. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347(20): 1557-65[DOI][PubMed]
  • 5. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003; 107(3): 391-7[PubMed]
  • 6. Albert MA, Glynn RJ, Ridker PM. Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation. 2003; 108(2): 161-5[DOI][PubMed]
  • 7. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001; 103(13): 1813-8[PubMed]
  • 8. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336(14): 973-9[DOI][PubMed]
  • 9. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342(12): 836-43[DOI][PubMed]
  • 10. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001; 344(26): 1959-65[DOI][PubMed]
  • 11. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001; 285(19): 2481-5[PubMed]
  • 12. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999; 99(2): 237-42[PubMed]
  • 13. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000; 321(7255): 199-204[PubMed]
  • 14. Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA. 2002; 288(8): 980-7[PubMed]
  • 15. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation. 2002; 105(22): 2595-9[PubMed]
  • 16. Mendall MA, Strachan DP, Butland BK, Ballam L, Morris J, Sweetnam PM, et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J. 2000; 21(19): 1584-90[DOI][PubMed]
  • 17. Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC/EACTS guidelines on myocardial revascularization. Rev Esp Cardiol (Engl Ed). 2015; 68(2): 144[DOI][PubMed]
  • 18. Storey RF, Judge HM, Wilcox RG, Heptinstall S. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thromb Haemost. 2002; 88(3): 488-94[DOI][PubMed]
  • 19. Klinkhardt U, Graff J, Harder S. Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model. Clin Pharmacol Ther. 2002; 71(3): 176-85[DOI][PubMed]
  • 20. Vivekananthan DP, Bhatt DL, Chew DP, Zidar FJ, Chan AW, Moliterno DJ, et al. Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am J Cardiol. 2004; 94(3): 358-60[DOI][PubMed]
  • 21. Quinn MJ, Bhatt DL, Zidar F, Vivekananthan D, Chew DP, Ellis SG, et al. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2004; 93(6): 679-84[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader